Investigating the Safety and Efficacy of SHR6508 Injection in the Treatment of Secondary Hyperparathyroidism in Hemodialysis Patients : A Multicenter, Long-term Clinical Trial

NCT06236295 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

303

Enrollment

INDUSTRY

Sponsor class

Conditions

Secondary Hyperparathyroidism (SHPT) in Subjects With Chronic Kidney Disease (CKD) on Hemodialysis

Interventions

DRUG: SHR6508

Sponsor

Shanghai Hengrui Pharmaceutical Co., Ltd.